Nothing Special   »   [go: up one dir, main page]

WO1996029410A1 - In vivo generation of antibodies against antigens secreted in a host by transfected mel cells - Google Patents

In vivo generation of antibodies against antigens secreted in a host by transfected mel cells Download PDF

Info

Publication number
WO1996029410A1
WO1996029410A1 PCT/GB1996/000616 GB9600616W WO9629410A1 WO 1996029410 A1 WO1996029410 A1 WO 1996029410A1 GB 9600616 W GB9600616 W GB 9600616W WO 9629410 A1 WO9629410 A1 WO 9629410A1
Authority
WO
WIPO (PCT)
Prior art keywords
host
mel
antibodies
biological
interest
Prior art date
Application number
PCT/GB1996/000616
Other languages
French (fr)
Inventor
Maurice Ronald Charles Needham
Melvyn Hollis
Original Assignee
Zeneca Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Limited filed Critical Zeneca Limited
Priority to EP96906864A priority Critical patent/EP0817848A1/en
Priority to JP8528176A priority patent/JPH11502116A/en
Publication of WO1996029410A1 publication Critical patent/WO1996029410A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • the present invention relates to methods for the generation of antibodies.
  • it relates to the use of live, secretory cells in such methods.
  • mice which have been injected with transfected murine erythroleukaemia (MEL) cells. This was gratifying since it was unclear whether or not the cells expressing the recombinant protein, or the expressed protein itself would remain in the tissue for sufficient time for a significant immune response to occur. Failure to observe tumour formation in animals which had been injected with the recombinant cells indicated that the cells at least were being rapidly cleared from the animal tissues.
  • MEL murine erythroleukaemia
  • a method for the generation in a mammalian host of antibodies to a biological of interest comprises incorporating murine erythroleukaemia (MEL) cells comprising DNA encoding the biological of interest into the mammalian host, allowing the MEL cells to express and secrete the biological of interest, allowing the host to raise antibodies thereto, and isolating said antibiodies from the host.
  • MEL murine erythroleukaemia
  • the mammalian host is conveniently a non-human animal such as a rat or a mouse, preferably a mouse.
  • the biological of interest comprises any convenient protein to which antibodies may be raised.
  • it may be a protein to which is difficult to raise or purify antibodies using presently available technology.
  • Such difficulties may also arise by virtue of the tissue or species of origin, for example proteins of human origin. It is conveniently introduced into the murine erythroleukaemia (MEL) cells via transfection with a vector.
  • MEL murine erythroleukaemia
  • Convenient vectors include the pEV expression vector.
  • the pEV expression vector is a modified version of the previously reported MEL expression vector pGSE1417/EC3 (Needham et al.. Nucleic Acids Research, 1992, __ (5), 997-1003). pEV was generated as follows :-
  • the EcoRI site in the thymidine kinase promoter, the Bglll site in the neomycin resistance gene and the NotI site in the LCR of pGSE1417 (20) were sequentially deleted by restriction enzyme digestion followed by T4 polymerase treatment and religation to generate pDGSE1417.
  • the Clal-Asp718 fragment from pEC3 (1) was ligated between the Clal and Asp718 sites of pDGSE1417 to generate pEV.
  • DNA encoding the biological of interest is introduced into the vector using conventional molecular biology techniques for example as disclosed by Maniatis si al in Molecular Cloning, A Laboratory Manual.
  • transfected MEL cells are conveniently incorporated into the mammalian host by injection, for example in the form of a bolus to be introduced subcutaneously or into the peritoneal cavity.
  • polyclonal antibodies are conveniently harvested from serum obtained from the mammal.
  • the use of splenic lymphocytes from animals immunised in this way can. via cell fusion, give rise to monoclonal antibody producing cell lines.
  • Such polyclonal and monoclonal antibodies represent further and independent aspects of the invention.
  • Example 1 The invention will now be illustrated but not limited by reference to the following Examples: Example 1
  • VCAM-1 cDNA Modification of VCAM-1 cDNA
  • VCAM-1 cDNA (Lobb et al., Biochem. and Biophys. Res. Comms.. 1991, US (3), pl498-1504) was obtained from British Biotechnology and was modified by polymerase chain reaction (PCR) procedures to
  • C.T.I. consensus translation initiation sequence immediately upstream of the translational start site (5' methionine).
  • MEL cell Expression of sVCAM-1 The modified sVCAM-1 cDNA was transferred into the MEL cell expression vector pEV (Needham et al., 1995, Protein Expression and Purification, _ (2), 1995). MEL C88 cells (Deisseroth et al. Cell, 1978, L5_, 55-63) were transfected with the pEV/sVCAM-1 expression construct. Six single cell clones and a population representing >200 clones were isolated, induced and tested for sVCAM-1 expression by VCAM-1 enzyme linked immunosorbent assay (ELISA). Initial ELISA results indicated that sVCAM-1 protein was expressed at between 1 and 5mg/ml. One clone (* 12) which expressed sVCAM-1 at 5mg/ml was selected for further studies.
  • ELISA VCAM-1 enzyme linked immunosorbent assay
  • MEL/sVCAM-1 clone *12 cells expressing were washed free from any residual culture medium using phosphate buffered saline (PBS) and then centrifuged to a soft pellet using a bench-top centifuge. The resultant slurry was diluted with fresh PBS to give a final concentration of 5x107 cells per lOOuls. lOOuls of cell suspension was injected as a subcutaneous bolus into the posterior flank of each of a group of 12 week old female Balb/C mice. This dose was repeated after 21 days and again after a further 14 days. Blood samples were taken on days 35 and 65.
  • PBS phosphate buffered saline
  • mice 12 weeks after the 3rd dose, the mice were each given a booster injection of 20ugs of purified recombinant VCAM protein contained in lOOuls of PBS. 4days later the mice were humanely culled and splenectomised and the splenocytes from 4 of their spleens used in fusion experiments with the NS0 myeloma cell line (Methods in Enzymology, 1981 , 73B:3). 2316 culture wells were set up following the fusion process and after biochemical selection using HAT medium (Littlefield, Experimental Cell Research, 1966. 41 1, 190) and growth in culture, 95 of these produced growing monoclonal cell colonies.
  • HAT medium Littlefield, Experimental Cell Research, 1966. 41 1, 190
  • Supernatant culture medium which was positive for anti-VCAM activity as judged by ELISA was produced by 16 of the 95. 12 of the 16 were recloned, by limiting dilution and 5 of the 12 produced clones which were postive for anti-VCAM activity. Examples of the positive clones were grown up to produce frozen stocks of the cell lines and exhausted supernatant from these cell lines was tested by ELISA and Western Blot analysis to confirm the continuance of monoclonal antibody activity.
  • MCP1 monoclonal anti-Monocyte Chemoattractant protein- 1
  • MCP-1 cDNA was isolated and modifed for expression as reported by Needham et al., Protein Expression and Purification, 1996, 2, 173-182.
  • the modified MCP-1 cDNA was transferred into the MEL cell expression vector pEV (Needham et al., 1995, Protein Expression and Purification, £ (2), 1995).
  • MEL C88 cells (Deisseroth et al, Cell, 1978, ___, 55-63) were transfected with the pEV/MCP-1 expression construct.
  • Six single cell clones and a population representing >200 clones were isolated, induced and tested for MCP-1 expression by Northern blot, calcium flux and chemotaxis assays and by mass spectrometry (Needham et al.. Protein Expression and Purification, 1996, 2, 173-182). Results indicated that MCP-1 protein was expressed at between 1 and 5mg/ml.
  • One clone (*5) which expressed MCP-1 at >5mg/ml was selected for further studies.
  • Antibody Generation This was performed exactly as for VCAM in Example 1 except that for antibody generation, the rest period between the last MEL cell injection and the pre-fusion booster was reduced to six weeks. Also 480 culture wells were set up after the fusion process and 35 of these produced growing monoclonal cell colonies. These eventually gave rise to 3 monoclonal antibody producing lines.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A method for the generation in a mammalian host of antibodies to a biological of interest which method comprises incorporating murine erythroleukemia (MEL) cell comprising DNA encoding the biological of interest into the mammalian host, allowing the MEL cells to express and secrete the biological of interest, allowing the host to raise antibodies thereto, and isolating said antibodies from the host.

Description

IN VIVO GENERATION OF ANTIBODIES AGAINST ANTIGENS SECRETED IN A HOST BY TRANSFECTED MEL CELLS
The present invention relates to methods for the generation of antibodies. In particular it relates to the use of live, secretory cells in such methods.
Available methods for the production of antibodies to a biological of interest are involved and have certain disadvantages. In particular they require the production of sufficient purified material to carry out the immunisation of animals. This may involve the use of cell cultures or tissues, fermentation broths, protein isolation and extraction from gels. affinity chromatography and other procedures.
We have now found that antibodies can be successfully raised in mice which have been injected with transfected murine erythroleukaemia (MEL) cells. This was gratifying since it was unclear whether or not the cells expressing the recombinant protein, or the expressed protein itself would remain in the tissue for sufficient time for a significant immune response to occur. Failure to observe tumour formation in animals which had been injected with the recombinant cells indicated that the cells at least were being rapidly cleared from the animal tissues.
Therefore in a first aspect of the invention we provide a method for the generation in a mammalian host of antibodies to a biological of interest which method comprises incorporating murine erythroleukaemia (MEL) cells comprising DNA encoding the biological of interest into the mammalian host, allowing the MEL cells to express and secrete the biological of interest, allowing the host to raise antibodies thereto, and isolating said antibiodies from the host.
The mammalian host is conveniently a non-human animal such as a rat or a mouse, preferably a mouse.
The biological of interest comprises any convenient protein to which antibodies may be raised. In particular it may be a protein to which is difficult to raise or purify antibodies using presently available technology. Such difficulties may also arise by virtue of the tissue or species of origin, for example proteins of human origin. It is conveniently introduced into the murine erythroleukaemia (MEL) cells via transfection with a vector.
Convenient vectors include the pEV expression vector. The pEV expression vector is a modified version of the previously reported MEL expression vector pGSE1417/EC3 (Needham et al.. Nucleic Acids Research, 1992, __ (5), 997-1003). pEV was generated as follows :-
The EcoRI site in the thymidine kinase promoter, the Bglll site in the neomycin resistance gene and the NotI site in the LCR of pGSE1417 (20) were sequentially deleted by restriction enzyme digestion followed by T4 polymerase treatment and religation to generate pDGSE1417. The Clal-Asp718 fragment from pEC3 (1) was ligated between the Clal and Asp718 sites of pDGSE1417 to generate pEV.
DNA encoding the biological of interest is introduced into the vector using conventional molecular biology techniques for example as disclosed by Maniatis si al in Molecular Cloning, A Laboratory Manual.
The transfected MEL cells are conveniently incorporated into the mammalian host by injection, for example in the form of a bolus to be introduced subcutaneously or into the peritoneal cavity.
The polyclonal antibodies are conveniently harvested from serum obtained from the mammal. The use of splenic lymphocytes from animals immunised in this way can. via cell fusion, give rise to monoclonal antibody producing cell lines. Such polyclonal and monoclonal antibodies represent further and independent aspects of the invention.
The invention will now be illustrated but not limited by reference to the following Examples: Example 1
Generation of anti-VCAM antibodies using recombinant MEL cell immunisation.
Modification of VCAM-1 cDNA:
VCAM-1 cDNA (Lobb et al., Biochem. and Biophys. Res. Comms.. 1991, US (3), pl498-1504) was obtained from British Biotechnology and was modified by polymerase chain reaction (PCR) procedures to
1) Remove unwanted 5' non-coding sequence.
2) Include a consensus translation initiation (C.T.I.) sequence immediately upstream of the translational start site (5' methionine).
(N.B. In addition this sequence was omitted for the purpose of baculovirus expression).
3) Terminate translation at the amino acid prior to the start of the transmembrane region (by introducing a translational stop codon at amino acid 72).
4) Include restriction enzyme sites at each end of the VCAM-1 cDNA to enable sub-cloning into a range of expression vectors.
MEL cell Expression of sVCAM-1 : The modified sVCAM-1 cDNA was transferred into the MEL cell expression vector pEV (Needham et al., 1995, Protein Expression and Purification, _ (2), 1995). MEL C88 cells (Deisseroth et al. Cell, 1978, L5_, 55-63) were transfected with the pEV/sVCAM-1 expression construct. Six single cell clones and a population representing >200 clones were isolated, induced and tested for sVCAM-1 expression by VCAM-1 enzyme linked immunosorbent assay (ELISA). Initial ELISA results indicated that sVCAM-1 protein was expressed at between 1 and 5mg/ml. One clone (* 12) which expressed sVCAM-1 at 5mg/ml was selected for further studies.
Antibody Generation: MEL/sVCAM-1 clone *12 cells expressing were washed free from any residual culture medium using phosphate buffered saline (PBS) and then centrifuged to a soft pellet using a bench-top centifuge. The resultant slurry was diluted with fresh PBS to give a final concentration of 5x107 cells per lOOuls. lOOuls of cell suspension was injected as a subcutaneous bolus into the posterior flank of each of a group of 12 week old female Balb/C mice. This dose was repeated after 21 days and again after a further 14 days. Blood samples were taken on days 35 and 65.
Solid phase enzyme linked immunosorbent assay (ELISA) of pooled serum samples using purified recombinant VCAM protein as antigen gave indicated 50% binding litres of : -
1 : 1400 at 35 days and
1 :6000+ at 65 days indicating that anti-VCAM polyclonal antibodies had been generated in the test animals.
12 weeks after the 3rd dose, the mice were each given a booster injection of 20ugs of purified recombinant VCAM protein contained in lOOuls of PBS. 4days later the mice were humanely culled and splenectomised and the splenocytes from 4 of their spleens used in fusion experiments with the NS0 myeloma cell line (Methods in Enzymology, 1981 , 73B:3). 2316 culture wells were set up following the fusion process and after biochemical selection using HAT medium (Littlefield, Experimental Cell Research, 1966. 41 1, 190) and growth in culture, 95 of these produced growing monoclonal cell colonies. Supernatant culture medium which was positive for anti-VCAM activity as judged by ELISA was produced by 16 of the 95. 12 of the 16 were recloned, by limiting dilution and 5 of the 12 produced clones which were postive for anti-VCAM activity. Examples of the positive clones were grown up to produce frozen stocks of the cell lines and exhausted supernatant from these cell lines was tested by ELISA and Western Blot analysis to confirm the continuance of monoclonal antibody activity.
Example 2
Generation of monoclonal anti-Monocyte Chemoattractant protein- 1 (MCP1 ) antibodies by recombinant MEL cell immunisation
Modification of MCP-1 cDNA: MCP-1 cDNA was isolated and modifed for expression as reported by Needham et al., Protein Expression and Purification, 1996, 2, 173-182.
Mel cell expression MCP-1 cDNA
The modified MCP-1 cDNA was transferred into the MEL cell expression vector pEV (Needham et al., 1995, Protein Expression and Purification, £ (2), 1995). MEL C88 cells (Deisseroth et al, Cell, 1978, ___, 55-63) were transfected with the pEV/MCP-1 expression construct. Six single cell clones and a population representing >200 clones were isolated, induced and tested for MCP-1 expression by Northern blot, calcium flux and chemotaxis assays and by mass spectrometry (Needham et al.. Protein Expression and Purification, 1996, 2, 173-182). Results indicated that MCP-1 protein was expressed at between 1 and 5mg/ml. One clone (*5) which expressed MCP-1 at >5mg/ml was selected for further studies.
Antibody Generation: This was performed exactly as for VCAM in Example 1 except that for antibody generation, the rest period between the last MEL cell injection and the pre-fusion booster was reduced to six weeks. Also 480 culture wells were set up after the fusion process and 35 of these produced growing monoclonal cell colonies. These eventually gave rise to 3 monoclonal antibody producing lines.

Claims

1. A method for the generation in a mammalian host of antibodies to a biological of interest which method comprises incorporating murine erythroleukaemia (MEL) cells comprising DNA encoding the biological of interest into the mammalian host, allowing the MEL cells to express and secrete the biological of interest, allowing the host to raise antibodies thereto, and isolating said antibodies from the host.
2. A method as claimed in claim 1 wherein the mammalian host is a non-human animal.
3. A method as claimed in claim 1 wherein DNA encoding the biological of interest is introduced into the MEL cells via transfection with a vector.
4. A method as claimed in claim 3 wherein the vector is the pEV expression vector.
5. A method as claimed in any one of the previous claims wherein the MEL cells are injected into the mammalian host.
6. A method as claimed in claim 5 wherein the MEL cells are injected in the form of a bolus to be introduced subcutaneously or into the peritoneal cavity.
7. Polyclonal antibodies produced using a method as claimed in any one of the previous claims.
8. Monoclonal antibodies produced using a method as claimed in any of claims 1 -6.
PCT/GB1996/000616 1995-03-22 1996-03-18 In vivo generation of antibodies against antigens secreted in a host by transfected mel cells WO1996029410A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP96906864A EP0817848A1 (en) 1995-03-22 1996-03-18 In vivo generation of antibodies against antigens secreted in a host by transfected mel cells
JP8528176A JPH11502116A (en) 1995-03-22 1996-03-18 In vivo formation of antibodies to antigens secreted in the host by transfected MEL cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9505777.4 1995-03-22
GBGB9505777.4A GB9505777D0 (en) 1995-03-22 1995-03-22 Process

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US08913790 A-371-Of-International 1997-09-19
US10/193,378 Continuation US20020182685A1 (en) 1995-03-22 2002-07-11 In vivo generation of antibodies against antigens secreted in a host by transfected MEL cells

Publications (1)

Publication Number Publication Date
WO1996029410A1 true WO1996029410A1 (en) 1996-09-26

Family

ID=10771639

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/000616 WO1996029410A1 (en) 1995-03-22 1996-03-18 In vivo generation of antibodies against antigens secreted in a host by transfected mel cells

Country Status (4)

Country Link
EP (1) EP0817848A1 (en)
JP (1) JPH11502116A (en)
GB (2) GB9505777D0 (en)
WO (1) WO1996029410A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011380A1 (en) * 1990-12-21 1992-07-09 Imperial Chemical Industries Plc Expression systems
WO1992016645A1 (en) * 1991-03-15 1992-10-01 Imutran Limited PROTEIN PRODUCTION FROM IMMORTAL CELLS GROWN $i(IN VIVO)
WO1995005853A1 (en) * 1993-08-26 1995-03-02 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011380A1 (en) * 1990-12-21 1992-07-09 Imperial Chemical Industries Plc Expression systems
WO1992016645A1 (en) * 1991-03-15 1992-10-01 Imutran Limited PROTEIN PRODUCTION FROM IMMORTAL CELLS GROWN $i(IN VIVO)
WO1995005853A1 (en) * 1993-08-26 1995-03-02 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
C. NEWTON ET AL.: "Cloning and expression in murine erythroleukemia cells: The soluble forms of the type I and type II tumor necrosis factor receptors fused to an immunogenic affinity tag.", PROTEIN EXPRESSION AND PURIFICATION, vol. 5, no. 5, October 1994 (1994-10-01), SAN DIEGO, CA, USA, pages 449 - 457, XP000574795 *
M. NEEDHAM ET AL.: "Further development of the locus control region/murine erythroleukemia expression system: High level expression and characterization of recombinant human calcitonin receptor.", PROTEIN EXPRESSION AND PURIFICATION, vol. 6, no. 2, April 1995 (1995-04-01), SAN DIEGO, CA, USA, pages 124 - 131, XP000574794 *
M. NEEDHAM ET AL.: "High level expression of human MCP-1 using the LCR/MEL expression system.", PROTEIN EXPRESSION AND PURIFICATION, vol. 7, no. 2, March 1996 (1996-03-01), SAN DIEGO, CA, USA, pages 173 - 182, XP000574796 *
M. NEEDHAM ET AL.: "LCR/MEL: A versatile system for high-level expression of heterologous proteins in erythroid cells.", NUCLEIC ACIDS RESEARCH, vol. 20, no. 5, 11 March 1992 (1992-03-11), OXFORD, GB, pages 997 - 1003, XP002007371 *
R. BRINES ET AL.: "Polyclonal activation of immature B cells by preactivated T cells: the role of IL-4 and CD40 ligand.", INTERNATIONAL IMMUNOLOGY, vol. 5, no. 11, November 1993 (1993-11-01), OXFORD, GB, pages 1445 - 1450, XP000574797 *

Also Published As

Publication number Publication date
GB9605619D0 (en) 1996-05-22
GB2299084B (en) 1997-03-26
EP0817848A1 (en) 1998-01-14
JPH11502116A (en) 1999-02-23
GB2299084A (en) 1996-09-25
GB9505777D0 (en) 1995-05-10

Similar Documents

Publication Publication Date Title
KR100186823B1 (en) Preparation and use of a human antibody gene bank(human antibody libraries)
US6214613B1 (en) Expression screening vector
US4663281A (en) Enhanced production of proteinaceous materials in eucaryotic cells
CA2466629C (en) Expression control using variable intergenic sequences
US4675285A (en) Method for identification and isolation of DNA encoding a desired protein
EP0173494A2 (en) Chimeric receptors by DNA splicing and expression
EP0332424A2 (en) Chimeric antibodies directed against human carcinoembryonic antigen
BG60444B2 (en) Method for the preparation of selected protein
JPS6147500A (en) Chimera monoclonal antibody and its preparation
EP1137808B1 (en) Methods for making recombinant cells
WO1989006694A1 (en) Process for selection of proteinaceous substances which mimic growth-inducing molecules
JPH07173200A (en) Multichain polypeptide or protein
WO1982001461A1 (en) Human hybridomas,precursors and products
JP2925181B2 (en) Methods for reducing the heterogeneity of monoclonal antibodies
JP2619232B2 (en) Gene system encoding human immunoglobulin E binding factor active polypeptide
EP0562123B1 (en) Novel physiologically active substance epimorphine, gene which codes for same, and antibody against epimorphine
EP0102634B1 (en) Recombinant dna, microorganism transformed therewith and use thereof
EP0511978B1 (en) Method of purifying recombinant polypeptides
AU5691998A (en) Reading frame independent epitope tagging
US20020182685A1 (en) In vivo generation of antibodies against antigens secreted in a host by transfected MEL cells
WO1996029410A1 (en) In vivo generation of antibodies against antigens secreted in a host by transfected mel cells
CN112251444B (en) Modified AMH gene sequence and method for preparing AMH by using same
EP0592230A1 (en) Human monoclonal anti-peptide anti-body and DNA encoding thereof
EP0493433B1 (en) Method for improving human monoclonal antibody production and cells used therein
EP0491351A2 (en) Chimeric antibodies and their use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996906864

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 913790

Date of ref document: 19970919

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 528176

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1996906864

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996906864

Country of ref document: EP